Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
Hot Flashes, Breast Cancer, Acupuncture
About this trial
This is an interventional treatment trial for Hot Flashes focused on measuring breast cancer, Acupuncture, hot flashes, Functional MRI
Eligibility Criteria
Inclusion Criteria:
- Aged 18-75 years old;
- Adjuvant hormone therapy (eg, tamoxifen and/or aromatase inhibitors) with or without ovarian function suppression has been administered for at least 4 weeks and is currently on treatment;
- Vasomotor syndrome for at least 6 weeks;
- Premenopausal or postmenopausal patients;
- Patients with persistent hot flashes for at least 4 weeks and with a frequency of more than 14 hot flashes per week (2 times per day) in the week before inclusion in the study, the weekly average hot flash composite score is 3-4;
- Patients after surgery and after chemotherapy (if any);
- Eastern Cooperative Oncology Group score of 0-1 points.
- Sign the informed consent and voluntarily participate in this clinical observation.
Exclusion Criteria:
- Tumor metastases, undergoing chemoradiotherapy or planning surgery;
- Pharmacological intervention for hot flashes with hot flash treatment drugs such as selective serotonin reuptake inhibitors (SSRIs) and/or anticonvulsants for at least 4 weeks prior to study initiation;
- Unstable heart disease or myocardial infarction within 6 months prior to study start;
- Started or changed adjuvant hormone therapy within the past week, or who planned to start or change adjuvant hormone therapy in the past 14 weeks;
- Seizures of unknown likelihood or history of seizures;
- Have used acupuncture for hot flashes within 6 months prior to the start of the study;
- Pregnant or breastfeeding patients;
- Apparent uncontrolled infection;
- Mental illness or family history; neurological disorder or family history.
Sites / Locations
- Jiangsu Province Hospital of Traditional Chinese Medcine
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Sham Comparator
No Intervention
Treatment group A
Treatment group B
control
Treatment group A was given endocrine and acupuncture treatment for 8 weeks (24 times in total, 3 times a week); followed up for 16 weeks, no acupuncture treatment.
Treatment group B was given endocrine and sham acupuncture treatment for 8 weeks, followed up for 16 weeks, no acupuncture during the period, and after 16 weeks, received standardized acupuncture for 8 weeks (24 times in total, 3 times a week).
The control group was given conventional adjuvant endocrine therapy, premenopausal patients received tamoxifen therapy, and postmenopausal patients received aromatase inhibitor or tamoxifen therapy.